Patients with papillary renal cell carcinoma (pRCC) have a low risk of tumor recurrence and cancer-related death after surgery, according to a study of 577 pRCC patients (mean age 62.4 years) across Italy.
Most patients (62%) had undergone radical nephrectomy surgery for tumors ranging in size from 3-7 cm (median 4.3 cm). After a median follow-up of 39.2 months, 81% of these individuals were alive and disease-free, 14% had experienced disease progression, 11% had died from the disease, and 5% had died from other causes, researchers reported in BJU International (2012;109:1140-1146).
The 10-year estimated recurrence-free survival and cancer-specific survival were 73.1% and 83.3%, respectively.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.